UBS assumed coverage of AbbVie (ABBV) with a Neutral rating and price target of $240, up from $220. The firm sees a balanced risk/reward for the shares with competition emerging for the company’s blockbuster immunology drugs Skyrizi and Rinvoq in 2026 and 2027. It views AbbVie as fairly priced at current levels.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie: Premium Valuation, Strong Long-Duration Growth, but Balanced Risk/Reward Supports Hold Rating
- 3 Best Dividend Aristocrat Stocks to Buy in 2026
- AbbVie Targets Dry Eye Market With New ABBV-444 Trial: What Investors Should Watch
- Top drugmakers to enter agreements with U.S. to cut drug prices, Reuters says
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!